Street Calls of the Week
CAMBRIDGE, Mass. - BeiGene , Ltd. (NASDAQ:ONC) reported mixed first quarter 2025 results, with earnings beating expectations but revenue falling short on Wednesday.
The company’s shares were down 5.27% in premarket trading following the release.
The global oncology company posted adjusted earnings per share of $1.22, significantly above the analyst estimate of -$0.43. However, revenue of $1.12 billion missed the consensus forecast of $1.13 billion.
Total (EPA:TTEF) revenue grew 49% year-over-year, driven by a 62% increase in global sales of BRUKINSA to $792 million. The company achieved GAAP profitability for the first time this quarter.
"We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth," said John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene.
BeiGene maintained its full year 2025 revenue guidance of $4.9-5.3 billion, in line with analyst expectations of $5.09 billion.
The company highlighted that BRUKINSA is now the overall BTK inhibitor market share leader in the U.S. for new chronic lymphocytic leukemia patient starts across all lines of therapy.
BeiGene plans to host an Investor R&D Day on June 26 to showcase its emerging breast cancer franchise and broader solid tumor portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.